Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28994369 | 0.98 | CHRM2 (0.63) | CHRM2CYP1A2ALDH1A1CYP2C19HRH3 | |
| SCHEMBL10939198 | 0.98 | CHRM2 (0.63) | CHRM2CYP1A2ALDH1A1CYP2C19HRH3 | |
| SCHEMBL5707525 | 0.95 | CYP1A2 (0.61) | CHRM2CYP1A2ALDH1A1CYP2C19HRH3 | |
| SCHEMBL6752172 | 0.88 | CYP1A2 (0.65) | CHRM2CYP1A2ALDH1A1CYP2C19HRH3 | |
| SCHEMBL1921574 | 0.86 | HRH3 (0.70) | CHRM2CYP1A2ALDH1A1CYP2C19HRH3 | |
| SCHEMBL2188467 | 0.85 | CHRM2 (0.77) | CHRM2ALDH1A1HRH3LMNASIGMAR1 | |
| SCHEMBL23053146 | 0.84 | CYP1A2 (0.69) | CHRM2CYP1A2ALDH1A1CYP2C19HRH3 | |
| SCHEMBL8510594 | 0.83 | CHRM2 (0.81) | CHRM2ALDH1A1HRH3ALOX15 | |
| SCHEMBL28375831 | 0.83 | CHRM2 (0.81) | CHRM2ALDH1A1HRH3ALOX15 | |
| SCHEMBL22118357 | 0.83 | CHRM2 (0.81) | CHRM2ALDH1A1HRH3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | GIVAUDAN SA (CH) | 2011-08-18 | — | — | US | disclosed |
| EP-2342180-A2 | ORGANIC COMPOUNDS SUITABLE FOR MODULATING FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2011-07-13 | — | — | EP | disclosed |
| US-7923461-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-04-12 | — | — | US | disclosed |
| EP-1568692-B1 | (Pyridinyl)alkyl-amides or -ureas as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-7741346-B2 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| WO-2010037244-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-04-08 | — | — | WO | disclosed |
| US-20100016380-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1743885-B1 | 1-[(adamantyl)alkyl]-3-[(pyridinyl)alkyl]urea compounds as TNF-.alpha inhibitors useful for autoimmune diseases | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-7491739-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080182881-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080161270-A1 | Angiogenesis inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-7345064-B2 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| EP-1743885-A2 | TNF-Alpha Produktion Hemmer zur Behandlung von Autoimmunerkrankungen | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20060229342-A1 | TNF-a production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7098226-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| EP-1568692-A1 | (pyridin-4-yl)alkyl-amides as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | TNFRSF1A, FFAR4, NGFR | CHRM2 480/4885CYP1A2 634/4885ALDH1A1 557/4885 |
| US-20060229342-A1 | TNF-a production inhibitors | TNF, TNFRSF1A, TNFRSF9 | CHRM2 656/4885CYP1A2 761/4885ALDH1A1 950/4885 |
| US-20080182881-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | CHRM2 507/4885CYP1A2 812/4885ALDH1A1 964/4885 |
| US-20080161270-A1 | Angiogenesis inhibitors | FLT4, KDR, FLT1 | CHRM2 1577/4885CYP1A2 1722/4885ALDH1A1 1014/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | CHRM2 1686/4885CYP1A2 1716/4885ALDH1A1 1011/4885 |
| US-20110200549-A1 | Organic Compounds Suitable For Modulating Fragrance Compositions | CYP2A6, CYP2B6, CYP2A13 | CHRM2 755/4885CYP1A2 11/4885ALDH1A1 99/4885 |
| US-20030032623-A1 | Tnf-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | CHRM2 1511/4885CYP1A2 718/4885ALDH1A1 556/4885 |
| US-20100016380-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | CHRM2 374/4885CYP1A2 929/4885ALDH1A1 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.